receiving concomitant therapy with aspirin. The company is now
concluding a second clinical pharmacology study of the effects of DG041
when taken with aspirin and Plavix(TM). deCODE is also working on a
once-daily formulation for DG041 and is exploring partnership
opportunities for the latter phases of development of DG041.
-- Nicotine addiction and lung cancer. In April, deCODE scientists
reported a clear link between a single SNP and susceptibility to
nicotine dependence. Moreover, in part because of this impact on
smoking behavior, each copy of the risk variant of this SNP confers an
approximately 30% increase in risk of lung cancer and a 20% increase in
risk of peripheral arterial disease (PAD), a common and debilitating
constriction of the arteries to the legs. Roughly half of people of
European descent carry at least one copy of the variant, which the
deCODE team estimates to account for some 18% of lung cancers and 10%
of cases of PAD. These are also perhaps the highest-impact risk factors
yet found for either condition. deCODE plans to apply these findings in
the development of a DNA-based test which can be used to aid in
personalizing and increasing the effectiveness of smoking cessation
efforts, and of predicting risk of lung cancer and PAD.
deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of diagnostics and drugs for common diseases.
deCODE is a global leader in gene discovery - our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
Through its CLIA
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved